Clinical trial technology platform Inato, based in Paris, France, has closed a $20 million Series A funding from investors including Cathay Innovation, Obvious Ventures, La Maison and Top Harvest Capital. With the new funding, Inato will advance its diversity product offering to meet the new FDA requirements. The company will also invest in oncology-specific innovation […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!